

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

# Factors Related to the Utilization of Digital Adherence Technologies in Tuberculosis Care: A Qualitative Study Among Adults in DS-TB Treatment, Health Care Providers and Other Key Stakeholders in Tanzania

## Authors

Bianca Gonçalves Tasca<sup>1</sup>, Andrew Mganga<sup>2</sup>, Chung Lam Leung<sup>1</sup>, Lucas Shilugu<sup>2</sup>, Christopher Pell<sup>1</sup>, Baraka Onjare<sup>2</sup>, Nicholaus Luvanda<sup>2</sup>, Liza de Groot<sup>1</sup>, Kristian van Kalmthout<sup>1</sup>, Katherine Fielding<sup>3</sup>, Degu Jerene<sup>1</sup>

## Affiliations

<sup>1</sup> KNCV Tuberculosis Foundation, the Hague, Netherlands  
<sup>2</sup> KNCV Tuberculosis Foundation, Dar es Salaam, Tanzania  
<sup>3</sup> TB Centre and Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK

## Abstract:

Numerous challenges, such as lengthy treatment courses, side effects, and distance to healthcare facilities contribute to suboptimal Tuberculosis (TB) treatment completion. Digital adherence technologies (DATs), such as smart pillboxes and medication labels, could be an alternative to facilitate TB treatment continuation.

In-depth interviews with people undergoing treatment for drug susceptible TB, health care providers (HCPs) and other key stakeholders were conducted to evaluate their experiences with DATs in ten health facilities across four different regions in Tanzania. This study is part of a multi country cluster randomized trials conducted under the ASCENT consortium.

Interviews were conducted with a total of 41 individuals, 19 people with TB and 22 HCPs and key stakeholders. One of the main findings indicates that participants found that the daily reminders

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

32 provided by the DATs, particularly the alarm from the smart pillboxes, helped in supporting  
33 treatment continuation and establishing a routine around medicine intake. DATs use was linked with  
34 reducing the financial burden of treatment, improving people with TB-HCPs relationship, and  
35 decreasing workload for HCPs. Although DATs were generally perceived as reliable, occasional  
36 technical malfunctions, such as battery depletion in smart pillboxes, were reported. The requirement  
37 of having access to a cellphone and a power source emerged as specific barriers for medication label  
38 users.

39 This study highlights the initial willingness and sustained enthusiasm for using DATs among  
40 respondents. DATs were perceived as useful tools, aiding individuals with treatment continuation  
41 through daily reminders and fostering stronger connections with HCPs. Nevertheless, issues such as  
42 poor network connectivity and the need for access to a working cellphone posed difficulties in  
43 usage. Findings from this study suggest the potential for improvements in the technologies and  
44 indicate that a thorough assessment of people's life conditions and needs prior to treatment  
45 initiations is important to determine the suitability of providing a DAT.

46

## 47 **Introduction**

48 Tuberculosis (TB) continues to be a major global public health challenge, affecting an  
49 estimated 10.6 million individuals worldwide and resulting in 1.3 million deaths in 2022 [1], despite  
50 being preventable and curable. Identifying and promptly treating individuals affected by TB and  
51 ensuring they have optimal conditions to complete the treatment has the potential to save millions  
52 of lives and eliminate the transmission of TB [2].

53 With around half the people with TB in the 30 high-burden countries successfully completing  
54 their treatment, there are concerning gaps in the TB care cascade [3]. Lengthy treatment duration  
55 and potential side effects are known to contribute to treatment discontinuation [4]. Other factors,  
56 such as forgetting to take medication, lack of knowledge about the importance of completing the

57 treatment, drug stockouts, distance to the healthcare facility and stigma, also negatively impact  
58 treatment continuation [5,6].

59 Directly observed therapy (DOT) has been the standard recommendation to enhance  
60 completion in TB treatment [7]. However, implementing strict DOT has posed challenges over the  
61 years. Frequent visits to clinics increased the workload for healthcare providers (HCPs) and created  
62 barriers for individuals on treatment due to extra costs associated with frequent travel [8]. In light of  
63 these challenges, digital adherence technologies (DATs) have emerged as possible alternatives to  
64 enhance TB treatment completion and improve outcomes. Recognizing the potential of digital  
65 solutions, the World Health Organization (WHO) issued recommendations regarding the  
66 implementation of DATs as part of integrated patient care [9].

67 DATs, such as cellphone-based reminders and smart pillboxes, have demonstrated the  
68 potential to enhance treatment initiation and completion in TB care [4]. A prior study conducted in  
69 Tanzania, involving people living with TB and HCPs utilizing medication labels (99 DOTs) for  
70 treatment support, revealed that HCPs believed the technology aided them in delivering better  
71 treatment, while people living with TB concurred that it facilitated their treatment continuation [10].  
72 However, more in-depth information regarding user-related factors and the usage of DATs in TB  
73 treatment is needed to strengthen the evidence base.

74 For DATs to be effective, they must accommodate the needs and preferences of both people  
75 with TB and HCPs. In order to understand the factors that influence experiences with using and  
76 implementing medication labels, smart pillboxes and the EverWell adherence platform, we  
77 conducted in depth interviews with people living with drug susceptible TB (DS-TB), HCPs and other  
78 key stakeholders in Tanzania. This qualitative study is part of a multi-country, cluster-randomized  
79 trials, the Adherence Support Coalition to End TB (ASCENT) consortium [11].

80

## 81 **Methods**

## 82 **Study Setting**

83           The ASCENT cluster randomized trials were conducted in Ethiopia, Tanzania, The Philippines,  
84 South Africa, and Ukraine. Two separate randomization processes occurred prior to the  
85 commencement of the study. Firstly, health facilities were randomized to either the intervention or  
86 the standard of care arm. A second randomization process determined the type of DAT provided at  
87 each intervention arm facility. People with TB enrolled in the intervention arm were offered either a  
88 smart pillbox or medication labels, depending on the health facility they received care from. If a  
89 person didn't have access to a cellphone in a health facility that provided medication labels, then a  
90 smart pillbox would be offered as an alternative solution. HCPs used the EverWell adherence  
91 platform to monitor DATs engagement, a proxy for adherence to treatment regimens.

92           Smart pillboxes are devices for storing TB medications. They provide users with audio-visual  
93 reminders and maintain a record of each instance the box is opened, transmitting this dosing history  
94 to the adherence platform. Conversely, medication labels consist of blisters packs with printed  
95 codes. These codes are used by people with TB to report their medication intake via toll-free SMS  
96 texts. In the event that a person living with TB fails to open the box or sends an SMS text - proxies of  
97 medication intake - an automatic message is dispatched to their cellphone (or cellphone they have  
98 access to) as a reminder to take their prescribed medicine.

99           For HCPs, the adherence platform offered daily adherence data accessible through a web-  
100 based dashboard or smartphone app. In cases where people with TB were observed to have missed  
101 their medication, HCPs were instructed to initiate a differentiated care approach, including home  
102 visits to individuals who had missed their doses for three consecutive days. Prior to the start of the  
103 intervention, healthcare workers received training on the proper use of DATs and the adherence  
104 platform. Training was provided once for two days at the beginning of the project for all HCPs.  
105 ASCENT staff also provided monthly technical support on demand throughout the trial  
106 implementation period, including quarterly supportive supervision.

107           In Tanzania, DATs were implemented in 36 health facilities [11] as part of the ASCENT

108 intervention. With an estimated population of 58 million in 2019 [12], the country is among the  
109 three high TB burden countries that reached or surpassed the initial milestones of the End TB  
110 Strategy for reducing both TB incidence and deaths by 2019. Tanzania, however, is still categorized  
111 as a high-burden country for TB and HIV-associated TB [13]. Studies conducted in the country have  
112 shown suboptimal treatment completion rates, with only 79% of people with TB achieving 95%  
113 adherence levels in the Kilimanjaro region [9].

114 TB treatment in Tanzania is administered through the primary healthcare network under the  
115 guidance of the National TB Programme. The treatment approach emphasizes patient-centered care,  
116 with a predominance of self-administered and home-based treatment modalities. The provision of  
117 free TB care in Tanzania aims to ensure universal access to treatment and mitigate the  
118 socioeconomic burden associated with the disease [12].

119

## 120 **Study Population**

121 In this qualitative evaluation, the study population encompassed people with TB using DATs  
122 for their DS-TB treatment at ASCENT facilities, HCPs, and other key stakeholders, from the four study  
123 regions in Tanzania: Arusha, Geita, Manyara and Mwanza. Interviews were conducted in 10  
124 randomly selected facilities, ensuring diverse representation based on the type of DAT used.  
125 Recruitment of people with TB occurred between April 1st, 2022, and July 30th, 2022. HCPs and  
126 other key stakeholders were recruited from January 22nd, 2023, to March 31st of the same year.  
127 Participants were invited to join the study via phone calls, with people with TB contacted by HCPs,  
128 and HCPs and other key stakeholders contacted by ASCENT staff. All interviews were conducted by  
129 ASCENT staff.

130 Eligibility criteria for people with TB included being at least 18 years old and receiving drug-  
131 susceptible TB (DS-TB) treatment using a DAT for a minimum of one month. Exclusion criteria  
132 encompassed individuals diagnosed with multi-drug-resistant TB (MDR-TB). HCPs were invited to  
133 participate in the interviews if they were over 18 years old and held positions as clinical officers,

134 nurses, or community health workers at one of the thirty-six health facilities involved in the  
135 intervention arm. Additionally, professionals from the Ministry of Health/National TB program and  
136 ASCENT research staff were also invited to partake in the interviews.

### 137 **Data collection**

138 An initial sample size of twenty people living with TB and twenty HCPs and other key  
139 stakeholders was established. Interviews were conducted until research interviewers perceived data  
140 saturation. In-depth interviews with people with TB took place during their routine visits to health  
141 facilities, where a private and quiet space was allocated for the interviews. Key stakeholders and  
142 HCPs interviews were prearranged and conducted in private office spaces to maintain  
143 confidentiality. The interviews followed an interview guide of open questions drawn from key  
144 themes and used in a flexible manner to capture each participant's unique experiences. Among  
145 individuals living with TB, interviews explored topics such as, participants' social relations, barriers  
146 and facilitators to treatment completion, technology literacy, and their understanding and appraisal  
147 of the DATs. Interviews were conducted from February to September 2022.

148 Within the group of key stakeholders and HCPs, interviews explored their experiences in  
149 delivering TB treatment through DATs, using the adherence platform, implementing differentiated  
150 responses, and their perspectives on the feasibility of integrating DATs within the differentiated  
151 model of care. Interviews were conducted in Kiswahili and audio recorded using portable sound  
152 recorders. Interviewers, AM, LS and NL were experienced in conducting qualitative interviews with  
153 TB/HIV clients. They had received post-graduate training in research methods and were oriented on  
154 the use of the interview guide.

155

### 156 **Data processing and analysis**

157 Interviews recordings were transcribed verbatim and subsequently translated into English by  
158 AM and LS. The analysis process was undertaken by three additional researchers, BT, LG and AL, with  
159 regular discussions with AM and DJ. Initially, all interview transcripts were thoroughly read by both

160 researchers to gain familiarity with the content. Subsequently, relevant codes were developed,  
161 taking in consideration the study's objectives. Once patterns in the data were identified, themes  
162 were defined, and thematic analysis sessions were conducted to achieve a final consensus on the  
163 relevant themes. The selection of themes was based on their thematic relevance to the research aim  
164 [14]. The data were analyzed using NVivo 12 qualitative analysis software and Microsoft Excel.

165 For this study, a practical thematic analysis approach was adopted, employing a hybrid  
166 analysis [15]. This approach entailed the utilization of both inductive and deductive methods, along  
167 with semantic and latent thematic analysis techniques, to develop the codes and derive meaningful  
168 insights from the data.

169

## 170 **Ethical Approval**

171 Ethical approval to the study was obtained from the World Health Organization (WHO) Ethics Review  
172 Committee, the London School of Hygiene & Tropical Medicine (LSHTM), and Tanzania's National  
173 Institute for Medical Research (NIMR) as a sub study under the overall ASCENT protocol. Prior to  
174 participation, written informed consent was obtained from all participants, and the sessions were  
175 audio recorded for transcription purposes.

176

## 177 **Results**

178 Of the 41 respondents interviewed, 19 were people with TB, and 22 were HCPs and other  
179 key stakeholders. Among people with TB, five were using medication labels and 14 were using the  
180 smart pillbox at the time of the interview. One of the participants using the smart pillbox had  
181 transitioned from the medication label during the trial due to cellphone damage. Among the people  
182 with TB who were interviewed, 11 (58%) were males and eight (42%) were between 30-39 years of  
183 age. In three instances people with TB were interviewed alongside their caregivers. This approach  
184 was adopted to address language barriers and/or assist elderly participants.

185 Key stakeholders and HCPs who took part in the research comprised community health  
186 workers, nurses, district TB and Leprosy coordinators and ASCENT research staff. Key stakeholders  
187 and HCPs participating in the study had a diverse range of years of experience in their respective  
188 roles, going from 1 to 14 years. Table 1 shows the characteristics of the interviewees.

189

190

191 **Table 1: People with TB, HCPs and key stakeholders’ demographic characteristics**

People with TB		N (%)	
<b>DAT type used at the moment of the interview</b>			
Smart Pillbox		14 (74%)	
Medication Label		5 (26%)	
<b>Sex</b>			
Male		11 (58%)	
Female		8 (42%)	
<b>Age range (years)</b>			
18-29		2 (11%)	
30-39		8 (42%)	
40-49		5 (26%)	
50-59		0 (0)	
≥60		4 (21%)	
<b>Total</b>		<b>19</b>	
<b>Key stakeholders and HCPs</b>		<b>N (%)</b>	
Community health Worker		4 (18%)	
Nurse		8 (36%)	
District TB and Leprosy coordinator		3 (14%)	
ASCENT Research Staff		1 (5%)	
Regional TB and Leprosy coordinator		4 (18%)	
Regional TB and HIV officer		2 (9%)	
<b>Total</b>		<b>22 (100%)</b>	
	Min.	Mean	Max.
HCPs and other key stakeholders years of experience	1	5	14

192

193

194 In the context of the ASCENT intervention, nurses reported handling tasks such as enrolling  
195 people with TB in the adherence platform, and initiating them on treatment, whereas community  
196 health workers focused on treatment follow-up and home visits. Other key stakeholders, including  
197 the Regional TB and Leprosy Coordinator, Regional TB and HIV Officer, and District TB and Leprosy



198 Coordinator, described their main activities as ensuring DATs availability, organizing technical  
199 support, and providing oversight in ASCENT facilities. Meanwhile, ASCENT research staff managed  
200 routine activities like supportive supervision, monitoring treatment continuation via the EverWell  
201 adherence platform, communication with service providers, data collection for project studies, and  
202 offered technical support for the EverWell and DATs utilization.

203

#### 204 **Overall engagement with DATs**

205 People with TB and HCPs demonstrated an initial inclination to engage with the DATs.

206 Amongst respondents, it was widely reported that the technologies could make one's life easier and  
207 participants were willing to try the DATs. In the HCPs interviews, respondents described feeling a  
208 renewed motivation to work once they heard about the implementation of the DATs. The  
209 interviewed HCPs also reported a high rate of technology uptake among people with TB. People with  
210 TB described a willingness to adhere to treatment and seemed to understand the importance of  
211 concluding the full treatment course.

212

213 *"When patients come for starting TB treatment, they ask I hear there is this smart pillbox, I would*  
214 *love to have it for helping me with my medication."* (Nurse, #3516)

215

216 The ASCENT research team was responsible for training HCPs who subsequently instructed  
217 people with TB on using the DATs. HCPs indicated that these orientation sessions varied from fifteen  
218 minutes to two hours, depending on individual needs. Generally, nurses assumed the responsibility  
219 of conducting these instruction sessions.

220 People with TB said that they were satisfied with the instructions received. Participants  
221 recounted how adapting and incorporating the DATs into their daily routines was easy. Both  
222 technologies were referred to as user-friendly, demanding minimal effort. Frequently, they had  
223 acquaintances with prior experience of using DATs, which not only helped them better comprehend

224 the technology but also provided support in effectively using DATs.

225

226 *“It was easy for me to understand because one of my friends had already used the technology before*

227 *and he had explained the details to me; it helped me to be more accepting of using the technology.*

228 *So, I understood the health provider very easily.”* (Person with TB using medication labels, Male, Age:

229 30-39 years, #1908)

230 *“There is no challenge at all. It is easy to open, take the pills and close it. [There are] even no*

231 *difficulties in storing it .”* (Person with TB using a Smart Pillbox, Female, Age: 40-49 years, #2374)

232

## 233 **The perceived utility of DATs**

### 234 **Daily reminders and treatment routine**

235 People with TB emphasized that the alarm notifications and messages helped with

236 treatment continuation, averting missed doses. The daily reminders helped them create a structured

237 routine for medicine intake. People with TB said that just by seeing the smart pillbox they would

238 already remember to take the medicine. Similar feelings were shared when respondents considered

239 the viewpoint of their family members. They recounted how their relatives got involved in the

240 treatment process by reminding them to take their medicine whenever they saw the box or heard its

241 alarm.

242

243 *“Even myself by observing the box (smart pillbox) around, even if it is not yet time for taking the*

244 *medication, I will remember that this box reminds me to take medication when it reaches a particular*

245 *time”* (Person with TB using a Smart Pillbox , Female, Age: 40-49 years, #1535 )

246

247 Nonetheless, some people with TB expressed a desire to have the flexibility to change the

248 alarm volume for the smart pillboxes because there were instances when they could not hear the

249 alarm sounding. Participants using medication labels did not benefit from alarms and healthcare

250 workers mentioned that people using this technology would occasionally forget to send SMS  
251 notifications despite having taken their medication.

252

253 *“Mainly there are challenges with the 99 DOTS [medication labels], some [people with TB] most of*  
254 *the time they forget to send SMS, but they may have taken the medicines already.”* (District TB and  
255 Leprosy coordinator, #3819)

256

257 HCPs and other key stakeholders also pointed out that by engaging with a DAT, people with  
258 TB would become aware of the importance of staying on treatment and creating a routine around it.  
259 HCPs identified the adherence platform as another attribute of the DATs that helped people with TB  
260 in continuing the treatment because it helped prompt an action from their side and prevent people  
261 living with TB being lost to follow up.

262

263 *“The other benefit is that patients were not missing doses or dropping [out] from treatment, because*  
264 *we could easily notice that within a day or two and trace them to get the patient back [on their*  
265 *treatment].”* (Community Health Worker, #3314)

266

267 *“TB treatment takes six months. If taking medicine for a week tends to be a challenge, six months is a*  
268 *marathon. But through smart pillboxes, which remind patients when to take medication, the patients*  
269 *have been able to take their medicines daily and complete their treatment on time. And, in some*  
270 *cases, it does not only remind them to take their medication, but also in other activities, like waking*  
271 *up kids for schools, time to wake up for farming and milking the cattle.”* (ASCENT project staff,  
272 #3011)

273

#### 274 **Smart pillboxes as medicine storage devices**

275 Participants from all groups highlighted that the smart pillboxes are a useful storage device

276 for keeping medicine safe and away from dust and dirt. Nonetheless, some people with TB  
277 highlighted that the standardized features of the smart pillboxes did not consistently match their  
278 individual requirements. Some criticized the box for its compact size.

279

280 “It [smart pillbox] enables me to store my medicine. (...) I could have been storing medicine using  
281 papers/magazine which is not very safe as the medicine could get dirty at times.”

282 (Person with TB using a smart pillbox, Female, Age: ≥60 years, #2495)

283

#### 284 **Cost-saving and reduced travels with DATs**

285 Another perceived benefit arising from DAT utilization was the potential for cost savings.

286 When individuals were using a DAT, they were only required to visit the health facility once a month

287 to refill their medication, thereby reducing the necessity of additional trips to ensure medication

288 intake. This also allowed people with TB to maintain their normal routine and provided them with

289 additional time to rest, if needed. Key stakeholders highlighted the importance of such an aspect for

290 people living in remote areas and said this was an indication of how DATs could adapt well to

291 different contexts.

292

293 *“It reduces the hustle of constantly coming to the health facility just for the [DOT provider] to see if*

294 *you have really taken the medicine and saves travel costs to the health facility.”* (Person with TB

295 using Medication label, Male, Age: ≥60 years, #1498)

296 *“Among the benefits it has reduced financial costs for patients to visit facilities regularly particularly*

297 *those residing at far places”* (Nurse, #4122)

298

#### 299 **Managing care for the many**

300           According to HCPs and key stakeholders, the utilization of the adherence platform made the  
301 process of supporting treatment easier. HCPs reported being able to assess in a timely manner a  
302 large number of peoples' treatment continuity patterns. This alleviated their workload because they  
303 did not need to rely on previously time-consuming strategies, such as counting empty blisters, to  
304 assure users were taking medication as expected. They felt as if the workload had diminished  
305 because they could perform tasks faster. Work also became more efficient because they could focus  
306 their efforts on people that showed suboptimal treatment continuation on the platform and prompt  
307 the initiation of a differentiated response based on the adherence platform information.

308

309       *"This new [adherence platform] has simplified our work. For instance, when you enter the office in*  
310 *the morning, you look on the tablet to monitor adherence of the patients on treatment, we follow up*  
311 *on patients with bad adherence who can say that they experience network challenges or maybe they*  
312 *forgot on that day, or s/he has been hospitalized on that day, so ASCENT has been so useful on*  
313 *monitoring patients for us."* ( Nurse, #4122)

314

### 315 **Cellphone-related challenges and the use of medication labels**

316           The requirement of access to a cellphone prevented the widespread provision of the  
317 medication labels to people living with TB in Tanzania. It was not uncommon for people to share  
318 cellphones, lose the device during treatment, or change numbers. These factors, together with the  
319 need for access to a power source to charge the cellphone, made it challenging for people with TB to  
320 effectively engage with the medication labels.

321

322       *"The challenge is with charging the phone; some days it happens the phone has no power and has to*  
323 *be charged. As a result, you take the pills without sending the message."* (Person with TB using  
324 *medication label, Male, Age: 40-49 years, #1498)*

325       *"The challenges are with {medication} labels because of using cellphone, you may find a client has*

326 *lost their cellphone, and when they change for another SIM card, they won't tell you until you start*  
327 *follow up."* (Nurse, #3516)

328

### 329 **Technical issues and DATs**

330 Overall both technologies were described as generally reliable but not without technical  
331 malfunctions. People with TB on both the smart pillboxes and medication labels said that sometimes  
332 they would receive a reminder message even after opening the box/sending a message, leading to  
333 confusion. Other technical challenges specifically related to the smart pillboxes were the fact that  
334 the alarm would ring at incorrect times and battery depletion, which required people to go to the  
335 facility for charging. HCPs noted that people with TB often became concerned when encountering  
336 errors in the DATs. In response, during the instruction sessions, they began explaining that technical  
337 malfunctions could happen, to alert and reassure users. The adherence platform also presented  
338 errors from time to time, occasionally taking a long time to update medication intake information.

339

340 *"I got confused and I had to contact the nurse, the nurse said that I had to continue sending*  
341 *[confirmatory messages] to the number. I continued... most times I would get a message back [from*  
342 *the platform] other times I would get a message reminding me to take my medication in the*  
343 *evening."* (Person with TB using Medication label, Male, Age: ≥60 years, #1806)

344 *"Some days the adherence platform could not be accessible. This happens every now and then, so*  
345 *you may find red marks to all patient calendar as if patients have not taken their medicines while*  
346 *they did swallow because when we call them, they will say I did swallow the pills."* (Nurse, #2506)

347

348 Some people with TB faced intermittent network connection, which prevented them from  
349 being able to send or receive messages in a timely manner. HCPs described that such issues also  
350 affected users on smart pillboxes when the box could not synch with the platform until the person  
351 arrived in an area with network connection. This would make people with TB worry, and some

352 mentioned going to the health facility to seek guidance or even sending several messages in a day to  
353 ensure their medication intake was accurately recorded.

354

355 *“The other challenge is poor network on some days, which led to the message to fail to be delivered.*

356 *It appears like you did not take the medicine, whereas in fact you did take it, but due to poor network*

357 *the short text code could not be successfully sent.”* (Person with TB using Medication label, Male,

358 Age: 40-49 years, #2014)

359

## 360 **Social and interpersonal aspects of using DATs**

### 361 **Enhanced people with TB-HCPs relationship**

362 Among the perceived benefits of using DATs, people with TB described feeling connected to

363 HCPs facilitated by these technologies. They perceived HCPs as closer to them and found an added

364 value in terms of understanding that DATs facilitate HCPs tasks by automatically reporting their

365 medicine intake history.

366

367 *“The pill box has been helpful for quickly sending information to the nurse that I have taken*

368 *medication on that day. Just after opening the box the nurse will get to know I have taken the pills.”*

369 (Person with TB using Medication label, Male, Age: 30-39 years, #2301)

370 *“Using this technology helps simplify communication with the clinic. I get to inform the nurse every*

371 *day I take the pills, I see like I am together with the nurse.”* (Person with TB using Medication label,

372 Male, Age: ≥60 years, #2014)

373

374 HCPs echoed this impression, highlighting the positive impact on their relationship with

375 people with TB. They phrased this in terms of building greater trust and collaboration with people

376 with TB. Even though the information on the adherence platform can only be seen as a proxy for

377 medication intake, they perceived that they could trust that people were properly taking the

378 medication. Also, they described how people with TB could also have more trust in HCPs because  
379 they would be able to act quicker if they realized a person was not utilizing the technology.

380

381 *“The intervention has made us work together with the patients unlike in the past when we just  
382 provided the medicines to the patient and let them go until they return for refill in a week or two.  
383 Even if they experienced challenges/side effects on taking their pills it was difficult to know. So, I see  
384 the patients feel as if they are valued and closely cared for. When we follow up and ask them about  
385 their progress, they say thanks for caring about my health, thanks for calling to ask about my  
386 condition. So, this intervention has given us a close and friendly relationship with our patients”.*

387 *(Nurse, #2203)*

388

### 389 **Social networks as influencers in DATs usage**

390 People with TB described receiving encouragement to start using the DATs and continue  
391 their treatment. Some individuals mentioned familiarity with both the treatment and the DATs  
392 through friends and family previous experiences, which made it easier to understand and utilize the  
393 technology. People with TB themselves expressed a willingness to encourage other people to engage  
394 with the DATs.

395

396 *“Interviewer: So, disclosing using a DAT was not a problem to you?”*

397 *Person with TB: No, the thing is once you start using that thing, you will convince other people to use  
398 it because it’s sweet.” (Person with TB using Smart Pillbox, Male, Age: 40-49 years, #1663)*

399

400 HCPs noted that some people with TB had concerns about being seen with the smart  
401 pillboxes. This feeling appears to be particularly true among younger people who may feel 'shy'  
402 about carrying the devices. Additionally, HCPs have reported that people using the medication labels



403 may have concerns that others could access their cellphone messages and discover that they are  
404 undergoing TB treatment.

405

406 *“Some of the youth we registered to use pill boxes were worried on how to carry the pill box when they*  
407 *want to travel to somewhere else, unlike the elders who are just comfortable, the youth feel a bit shy*  
408 *or like how will people see me if I carry this pill box.” (Nurse, #2304)*

#### 409 **Cultural traditions and the reutilization of DATs**

410 Cultural traditions were raised as a potential obstacle for the reuse of smart pillboxes. In  
411 Tanzania, there exists a custom of burying individuals along with their possessions, and this has  
412 raised apprehensions among key stakeholders about the feasibility of re-using the DATs, even  
413 though there seemed to be limited instances of such occurrence.

414

415 *“ There is also an understanding challenge: you may tell a patient that this smart pillbox given to you*  
416 *will need to go to another patient after you are done with treatment and the treatment supporters*  
417 *may be present hearing that, but if that patient dies... in some society’s tradition, particularly some*  
418 *of our fellow Sukuma believe that when a patient dies, s/he should be buried with all of her/his*  
419 *treatment equipment, so these are among the challenges with DAT.” (ASCENT project staff, #3011)*

420

#### 421 **Discussion**

422 Tuberculosis treatment is a lengthy process that can pose numerous challenges, such as  
423 adverse reactions, which can lead to treatment interruptions [16]. DATs were designed to provide an  
424 additional layer of support, aiding individuals to follow their treatment regimen. The objective of the  
425 present study was to evaluate the firsthand experiences of individuals living with TB, HCPs and other  
426 key stakeholders within the Tanzanian healthcare system, regarding the utilization of DATs: the  
427 medication labels and the smart pillboxes alongside the adherence platform utilized by HCPs.

428 The findings indicate an initial willingness among participants to utilize DATs. HCPs indicated

429 a high acceptance among people with TB for utilizing DATs as part of their treatment, HCPs  
430 themselves were motivated to integrate these technologies into their daily work routines. This  
431 attitude appeared to persist even after participants experienced the technologies, as evidenced by  
432 people with TB predisposition of recommending DATs to others. This indicates an acceptance of the  
433 studied DATs, which aligns with findings from other studies conducted in Uganda and Tanzania,  
434 where the 99DOTS technology (medication label) was found to be highly acceptable among people  
435 with TB, HCPs, and TB officers [10,17]. Additionally, the smart pillboxes were also found to be  
436 associated with high degrees of satisfaction and acceptability among people with TB and healthcare  
437 workers in China [18].

438         During the interviews, engaging with DATs was generally seen as straightforward and  
439 requiring minimal effort. Training sessions seem to have had an important role in shaping this  
440 impression. Previous studies have also highlighted the need for training and follow-up advice  
441 sessions for appropriate engagement with the DATs, whereby sufficient orientation for HCPs, people  
442 with TB and their families was a necessary condition for appropriate technology engagement  
443 [17,19,20].

444         One of the standout advantages offered by DATs was their ability to prompt medication  
445 reminders, a feature associated with enhanced adherence, as recounted by people with TB and  
446 HCPs. DATs accomplish this through functionalities such as the alarm and messaging systems,  
447 engaging not just people with TB but also involving caregivers and family members as seen in the  
448 interviews. This benefit was mostly perceived by users of the smart pillboxes. The adherence  
449 platform was also seen as an important factor influencing treatment continuation because HCPs  
450 were able to target their actions to people with suboptimal treatment continuation. Similar findings  
451 were reported in a study conducted in India, where people with TB appreciated that smart pillbox  
452 reminders helped them maintain treatment consistency and avoid missing doses [20].

453         In the current study, participants reported a reduction in financial burden due to the DATs.  
454 This was linked to reduced journeys to the healthcare facilities and the ability to continue their

455 regular daily activities. This is consistent with findings from prior studies in which HCPs highlighted  
456 that people with TB, especially from rural areas who usually must travel long distances to reach a  
457 health unit, benefited from less frequent travelling [19,20]. This observation underscores the  
458 potential contribution of these technologies towards fulfilling a key objective of the End TB Strategy,  
459 which seeks to prevent individuals from incurring catastrophic costs related to TB [21].

460         The HCPs perception that DATs improved their work by enabling easy monitoring of  
461 individual's' medication intake and diminishing workload is another important perceived benefit of  
462 the DATs. In a previous study conducted in Tanzania, HCPs also reported a decrease in workload  
463 which enabled them to spend more quality time engaging with people with TB [10,19].

464         Network issues, along with the need for a cellphone and access to electricity, posed a  
465 significant barrier for the uptake of the medication label. Such an issue was already reported as an  
466 important limitation of this technology and although in the present study it was not possible to  
467 assess differences between area of living and socioeconomic strata, studies indicate that people  
468 living in rural areas and of low socio-economic levels might be the most affected by these issues  
469 [17,20].

470         In this study, DATs were seen as having the capacity to improve the relationship and  
471 collaboration between people living with TB and HCPs. People with TB have said to feel more  
472 connected to the HCPs and HCPs expressed feeling a greater sense of collaboration with patients.  
473 This was also reported in different studies where DATs appear to have contributed to the cultivation  
474 of mutual trust and care between individuals with TB and HCPs [10,17,22].

475         A small number of individuals with TB interviewed mentioned being reluctant to disclose  
476 their TB status or the usage of DATs. However, HCPs noted that younger participants expressed  
477 apprehension about using smart pillboxes due to concerns about potential stigmatization. This  
478 finding aligns with a study conducted in South Africa, where HCPs reported that people with TB  
479 struggled to keep their TB status concealed when using smart pillboxes. As a result, these individuals  
480 often left the devices behind when they needed to travel or go to work [20,24].

481 Cultural traditions were viewed as a potential obstacle to the reuse of DATs. Key  
482 stakeholders commonly believed that burial customs could be an obstacle to the sustainability of  
483 DATs implementation even though there was only one occurrence reported. Nevertheless,  
484 conducting further investigation and providing specific guidance on this matter could be a valuable  
485 initiative in this context.

#### 486 **Strengths and limitations**

487 The study is limited by the fact that participants were recruited through convenience  
488 sampling from health facilities, which meant that the perspectives of individuals that discontinued  
489 using DATs or were lost to follow up were not included. We can only partially grasp the impressions  
490 of the people with TB who experienced difficulties with their treatment regimen or with the DATs  
491 through the information that HCPs and key stakeholders provided. This also prevented us from  
492 gaining further insight into the differentiated response because only individuals with suboptimal  
493 treatment continuation would receive such care.

494 Two key strengths of the study are the diversity of roles held by the interviewed key  
495 stakeholders, which ensured a wide range of opinions, and the inclusion of participants from the  
496 four regions of the trial, enhancing the study's representativeness within the Tanzanian context.

497

#### 498 **Conclusions**

499 This study aimed to provide insights into the use of medication labels, smart pillboxes and  
500 the EverWell adherence platform, for TB treatment in Tanzania among people with TB, HCPs and  
501 other key stakeholders. Interviews suggest that respondents showed an initial willingness to accept  
502 the technologies, which was sustained after experiencing the tools.

503 The study findings underscore that DATs were seen as useful by participants but that the  
504 technologies' suitability is dependent on a person's life conditions and preferences. Factors such as  
505 owning a cellphone, access to reliable network and electricity, age, and socioeconomic status appear  
506 to influence the extent to which a person can benefit from these technologies.

507 To establish a more patient-centric approach to care, the decision regarding which DAT to  
508 use and whether to employ one should be thoroughly discussed and evaluated in consultation with  
509 the person initiating TB treatment. Further research, stratified by socioeconomic strata, could  
510 provide more insights into how well-suited these technologies are for benefiting those who are most  
511 in need.

512

### 513 **Acknowledgments**

514

515 The authors would like to thank all study participants for their valuable contributions.

516

517

### 518 **References**

519

- 520 1. Global tuberculosis report 2023. Geneva: World Health Organization; 2023.
- 521 2. Ryckman T, Robsky K, Cilloni L, Zawedde-Muyanja S, Ananthakrishnan R, Kendall EA, et al.  
522 Ending tuberculosis in a post-COVID-19 world: a person-centred, equity-oriented approach.  
523 Vol. 23, *The Lancet Infectious Diseases*. Elsevier Ltd; 2023. p. e59–66.
- 524 3. Kim J, Keshavjee S, Atun R. Health systems performance in managing tuberculosis: Analysis of  
525 tuberculosis care cascades among high-burden and non-high burden countries. *J Glob Health*.  
526 2019;9(1).
- 527 4. Zaidi HA, Wells CD. Digital health technologies and adherence to tuberculosis treatment. Vol.  
528 99, *Bulletin of the World Health Organization*. World Health Organization; 2021. p. 323-323A.
- 529 5. Msoka EF, Orina F, Sanga ES, Miheso B, Mwanyonga S, Meme H, et al. Qualitative assessment  
530 of the impact of socioeconomic and cultural barriers on uptake and utilisation of tuberculosis  
531 diagnostic and treatment tools in East Africa: A cross-sectional study. *BMJ Open*. 2021 Jul  
532 12;11(7).
- 533 6. Tesfahuneygn G, Medhin G, Legesse M. Adherence to Anti-tuberculosis treatment and  
534 treatment outcomes among tuberculosis patients in Alamata District, northeast Ethiopia.  
535 *BMC Res Notes*. 2015 Sep 29;8(1).
- 536 7. Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. *The*  
537 *Lancet*. 1995 Jun 17;345:1545–8.
- 538 8. Sagbakken M, Frich JC, Bjune GA, Porter JDH. Ethical aspects of directly observed treatment  
539 for tuberculosis: a cross-cultural comparison. *BMC Med Ethics*. 2013;14:25.
- 540 9. Sumari-De Boer M, Pima FM, Ngowi KM, Chelangwa GM, Mtesha BA, Minja LM, et al.  
541 Implementation and effectiveness of evriMED with short messages service (SMS) reminders  
542 and tailored feedback compared to standard care on adherence to treatment among

- 543 tuberculosis patients in Kilimanjaro, Tanzania: Proposal for a cluster randomized controlled  
544 trial. *Trials*. 2019 Jul 12;20(1).
- 545 10. Efo E, Onjare B, Shilugu L, Levy J. Acceptability, Feasibility and Accuracy of 99DOTS Adherence  
546 Technology in Mining Region of Tanzania. In: Cunningham M, Cunningham P, editors.  
547 Acceptability, Feasibility and Accuracy of 99DOTS Adherence Technology in Mining Region of  
548 Tanzania . 2021. p. 1–12.
- 549 11. Jerene D, Levy J, Van Kalmthout K, Rest J Van, McQuaid CF, Quaife M, et al. Effectiveness of  
550 digital adherence technologies in improving tuberculosis treatment outcomes in four  
551 countries: a pragmatic cluster randomised trial protocol. *BMJ Open*. 2023 Mar 14;13(3).
- 552 12. Kilale AM, Pantoja A, Jani B, Range N, Ngowi BJ, Makasi C, et al. Economic burden of  
553 tuberculosis in Tanzania: a national survey of costs faced by tuberculosis-affected  
554 households. *BMC Public Health*. 2022 Dec 1;22(1).
- 555 13. Global tuberculosis report 2022. Geneva: World Health organization; 2022.
- 556 14. Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol*. 2006;3(2):77–101.
- 557 15. Saunders CH, Sierpe A, Von Plessen C, Kennedy AM, Leviton LC, Bernstein SL, et al. Practical  
558 thematic analysis: a guide for multidisciplinary health services research teams engaging in  
559 qualitative analysis. *BMJ*. 2023;
- 560 16. Handbook for the use of digital technologies to support tuberculosis medication  
561 adherence. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO
- 562 17. Leddy A, Ggita J, Berger CA, Kityamuwesi A, Sanyu AN, Tinka LK, et al. Barriers and Facilitators  
563 to Implementing a Digital Adherence Technology for Tuberculosis Treatment Supervision in  
564 Uganda: Qualitative Study. *J Med Internet Res*. 2023;25.
- 565 18. Liu X, Blaschke T, Thomas B, De Geest S, Jiang S, Gao Y, et al. Usability of a medication event  
566 reminder monitor system (MERM) by providers and patients to improve adherence in the  
567 management of tuberculosis. *Int J Environ Res Public Health*. 2017 Sep 25;14(10).
- 568 19. Guzman K, Crowder R, Leddy A, Maraba N, Jennings L, Ahmed S, et al. Acceptability and  
569 feasibility of digital adherence technologies for drug-susceptible tuberculosis treatment  
570 supervision: A meta-analysis of implementation feedback. *PLOS Digital Health*. 2023 Aug  
571 15;2(8):e0000322.
- 572 20. Thomas BE, Kumar JV, Periyasamy M, Khandewale AS, Mercy JH, Raj EM, et al. Acceptability  
573 of the medication event reminder monitor for promoting adherence to multidrug-resistant  
574 tuberculosis therapy in two indian cities: Qualitative study of patients and health care  
575 providers. *J Med Internet Res*. 2021 Jun 1;23(6).
- 576 21. Mcquaid CF, Foster N, Quaife M, Levy J, Tadesse AW, Charalambous S, et al. Digital adherence  
577 technology for TB: Focus on livelihoods as well as lives. Vol. 25, *International Journal of*  
578 *Tuberculosis and Lung Disease*. International Union Against Tuberculosis and Lung Disease;  
579 2021. p. 416–7.
- 580 22. Thomas BE, Vignesh Kumar J, Onongaya C, Bhatt SN, Galivanche A, Periyasamy M, et al.  
581 Explaining differences in the acceptability of 99DOTS, a cell phone-based strategy for  
582 monitoring adherence to tuberculosis medications: Qualitative study of patients and health  
583 care providers. *JMIR Mhealth Uhealth*. 2020;8(7).

- 584 23. Iribarren SJ, Sward KA, Beck SL, Pearce PF, Thurston D, Chirico C. Qualitative evaluation of a  
585 text messaging intervention to support patients with active tuberculosis: Implementation  
586 considerations. JMIR Mhealth Uhealth. 2015 Mar 1;3(1).
- 587 24. Mukora R, Maraba N, Orrell C, Jennings L, Naidoo P, Mbatha MT, et al. Qualitative study  
588 exploring the feasibility of using medication monitors and a differentiated care approach to  
589 support adherence among people receiving TB treatment in South Africa. BMJ Open. 2023  
590 Mar 3;13(3).
- 591